President Donald Trump’s new pharmaceutical tariffs are set to reshape the global drug industry, as the United States seeks to reduce its dependence on foreign manufacturing and strengthen domestic production. However, the policy has raised concerns about rising drug prices, supply chain disruptions and reduced pharmaceutical innovation.
On September 29, 2026, the Trump administration implemented 100% tariffs on certain imported patented medicines and pharmaceutical ingredients. The measure aims to encourage drugmakers to relocate production to the United States. However, exemptions apply to major pharmaceutical companies with agreements to expand domestic manufacturing and lower drug prices, while generic medicines, orphan drugs and certain specialty medicines are largely excluded.
The policy targets an industry deeply integrated into global supply chains. The United States relies heavily on overseas manufacturers, particularly in India and China, for generic medicines and active pharmaceutical ingredients (APIs). More than 90% of US prescriptions are filled with generic drugs, while over 92% of facilities producing generic APIs for the US market are located overseas.
Although the tariffs are intended to encourage domestic production, relocating pharmaceutical manufacturing is complex and costly. Establishing new facilities requires significant investment, regulatory approvals, specialized equipment and skilled labor. These challenges are particularly difficult for small and midsize drugmakers that rely on contract manufacturers and have limited financial resources.
According to a preliminary analysis, more than 100 drugmakers produce at least one medicine that is not exempt from the tariffs. Industry experts warn that higher costs could force some smaller companies to merge with larger competitors, discontinue certain medicines or withdraw from the market. This could reduce competition, increase prices and limit treatment options for patients, particularly those with conditions served by smaller pharmaceutical companies.
The tariffs could also affect pharmaceutical logistics and distribution. In the United States, three major distributors control approximately 92% of pharmaceutical distribution revenue. Changes in sourcing and manufacturing locations could require companies to adjust transportation routes, inventory strategies and distribution networks, creating uncertainty for freight operators, importers, hospitals and pharmacies.
Meanwhile, the administration plans to introduce tariffs on imported generic medicines starting in August 2028, initially at 100%, with the rate potentially increasing to 200% in 2029. The phased approach is intended to give manufacturers time to establish domestic production. However, generic drugs operate on thin profit margins, making it uncertain whether tariffs alone will be sufficient to encourage companies to relocate manufacturing.
Beyond potential price increases and supply disruptions, industry representatives have warned that tariffs could divert resources away from research and development, slowing the discovery of new medicines. The Biotechnology Innovation Organization has argued that increased costs could undermine investment in pharmaceutical innovation.
Ultimately, Trump’s pharmaceutical tariffs highlight the challenge of balancing domestic manufacturing and national security objectives with affordable and reliable access to medicines. While reshoring could strengthen US production capacity over time, the transition may place financial pressure on smaller drugmakers and disrupt established global supply chains. The long-term impact will depend on how quickly domestic manufacturing expands and how companies adapt to the changing trade environment.
